Free Trial Information
BioCentury | Aug 21, 2006
Strategy

Targeted Genetics chronicles

...11/00 - Says it will spin out its cell therapy technology into a subsidiary called CellExSys...
...improvements in pulmonary function in a Phase II trial in CF (p=0.04) O. 10/10/02 - CellExSys...
Read More
BioCentury | Aug 21, 2006
Strategy

Learning through time

...desert that followed, TGEN monetized some assets, spinning off its ex vivo delivery technology into CellExSys Inc....
Read More
BioCentury | Aug 2, 2004
Company News

Chromos, Targeted Genetics deal

...CHR completed the acquisition of TGEN subsidiary CellExSys Inc. (Seattle, Wash.) for about C$4.5 million (US$3.4 million...
...see BioCentury, June 28). TGEN owned about 80% of CellExSys. The other shareholders were mainly CellExSys...
Read More
BioCentury | Jun 28, 2004
Company News

Chromos, Targeted Genetics deal

...CHR will acquire all of the outstanding shares of TGEN's majority-owned subsidiary CellExSys Inc. (Seattle, Wash.) for...
...TGEN would have up to a 15.5% stake in the company. CHR plans to merge CellExSys...
Read More
BioCentury | Oct 14, 2002
Company News

Targeted Genetics Inc., Itochu Corp. deal

...TGEN majority-owned subsidiary CellExSys Inc. (Seattle, Wash.) partnered with Itochu to form a Japanese joint venture to...
...manufacture CellExSys's cell therapy products in Japan. CellExSys received an undisclosed upfront payment from Itochu. CellExSys...
Read More
BioCentury | Oct 10, 2002
Company News

CellExSys, Itochu forming cell therapy JV

...manufacture CellExSys's cell therapy products in Japan. CellExSys received an undisclosed upfront payment from Itochu. CellExSys...
Read More
BioCentury | Dec 3, 2001
Clinical News

T cell expansion technology regulatory update

...TGEN's CellExSys Inc. majority owned subsidiary received U.S. Patent No. 6,316,257 covering in vitro production of antigen-specific...
...Patent No. 6,316,257 covering in vitro production of antigen-specific T cells. The patent relates to CellExSys'...
Read More
BioCentury | Jul 16, 2001
Company News

Targeted Genetics management update

...Seattle, Wash. Business: Gene/Cell therapy Hired: Phillip Maples as VP of technical operations at TGEN's CellExSys Inc....
Read More
BioCentury | May 14, 2001
Company News

CellExSys scientific advisory board update

CellExSys Inc., Seattle, Wash. Business: Gene/Cell therapy Appointed: Lewellys Barker, chief medical officer at Sequella Global Tuberculosis Foundation; Malcolm Brenner, professor of medicine and pediatrics at Baylor College of Medicine; Nathaniel Brown, SVP of hepatitis...
Read More
BioCentury | Mar 19, 2001
Company News

Targeted Genetics board of directors update

...Appointed to the board of TGEN subsidary CellExSys Inc. : H. Stewart Parker, TGEN president and CEO...
...Thomas Wiggans, president and CEO of Connetics Corp. ; and David Schubert, president of CellExSys...
Read More
Items per page:
1 - 10 of 13
BioCentury | Aug 21, 2006
Strategy

Targeted Genetics chronicles

...11/00 - Says it will spin out its cell therapy technology into a subsidiary called CellExSys...
...improvements in pulmonary function in a Phase II trial in CF (p=0.04) O. 10/10/02 - CellExSys...
Read More
BioCentury | Aug 21, 2006
Strategy

Learning through time

...desert that followed, TGEN monetized some assets, spinning off its ex vivo delivery technology into CellExSys Inc....
Read More
BioCentury | Aug 2, 2004
Company News

Chromos, Targeted Genetics deal

...CHR completed the acquisition of TGEN subsidiary CellExSys Inc. (Seattle, Wash.) for about C$4.5 million (US$3.4 million...
...see BioCentury, June 28). TGEN owned about 80% of CellExSys. The other shareholders were mainly CellExSys...
Read More
BioCentury | Jun 28, 2004
Company News

Chromos, Targeted Genetics deal

...CHR will acquire all of the outstanding shares of TGEN's majority-owned subsidiary CellExSys Inc. (Seattle, Wash.) for...
...TGEN would have up to a 15.5% stake in the company. CHR plans to merge CellExSys...
Read More
BioCentury | Oct 14, 2002
Company News

Targeted Genetics Inc., Itochu Corp. deal

...TGEN majority-owned subsidiary CellExSys Inc. (Seattle, Wash.) partnered with Itochu to form a Japanese joint venture to...
...manufacture CellExSys's cell therapy products in Japan. CellExSys received an undisclosed upfront payment from Itochu. CellExSys...
Read More
BioCentury | Oct 10, 2002
Company News

CellExSys, Itochu forming cell therapy JV

...manufacture CellExSys's cell therapy products in Japan. CellExSys received an undisclosed upfront payment from Itochu. CellExSys...
Read More
BioCentury | Dec 3, 2001
Clinical News

T cell expansion technology regulatory update

...TGEN's CellExSys Inc. majority owned subsidiary received U.S. Patent No. 6,316,257 covering in vitro production of antigen-specific...
...Patent No. 6,316,257 covering in vitro production of antigen-specific T cells. The patent relates to CellExSys'...
Read More
BioCentury | Jul 16, 2001
Company News

Targeted Genetics management update

...Seattle, Wash. Business: Gene/Cell therapy Hired: Phillip Maples as VP of technical operations at TGEN's CellExSys Inc....
Read More
BioCentury | May 14, 2001
Company News

CellExSys scientific advisory board update

CellExSys Inc., Seattle, Wash. Business: Gene/Cell therapy Appointed: Lewellys Barker, chief medical officer at Sequella Global Tuberculosis Foundation; Malcolm Brenner, professor of medicine and pediatrics at Baylor College of Medicine; Nathaniel Brown, SVP of hepatitis...
Read More
BioCentury | Mar 19, 2001
Company News

Targeted Genetics board of directors update

...Appointed to the board of TGEN subsidary CellExSys Inc. : H. Stewart Parker, TGEN president and CEO...
...Thomas Wiggans, president and CEO of Connetics Corp. ; and David Schubert, president of CellExSys...
Read More
Items per page:
1 - 10 of 13